Recent events
Recent events tied to this brand in public sources.
Back to profile9 entries
2022
Biocon announces Biocon Biologics–Covidshield Technologies merger
Biocon announced that its material subsidiary Biocon Biologics Ltd would merge with Serum Institute of India's wholly owned subsidiary Covidshield Technologies Pvt Ltd, subject to requisite approvals. Biocon Biologics will issue and allot 15% equity shares to Serum on a fully diluted basis.
2021
Serum Institute cuts Covishield price for state governments
Serum Institute of India announced a 25% reduction in its Covishield price for state governments, from Rs 400 to Rs 300 per dose, effective immediately. The article reports the reduction amid public criticism of vaccine pricing.
2021
Manjari plant fire to affect vaccine production
The Serum Institute of India said a fire at its Manjari plant would affect future production of BCG and Rota vaccines. The fire, which broke out in an under-installation building, killed five people; the article reports that a minister said the initial fire was caused by ongoing welding work.
2020
Serum Institute sues COVID-19 vaccine trial participant
Serum Institute of India sued a COVID-19 vaccine trial participant for defamation after he alleged that the trial caused serious side effects. The company rejected his allegations and said his illness was unrelated to the vaccine trial.
2020
Covishield trial volunteer sues Serum Institute over alleged adverse reaction
A 40-year-old Covishield trial volunteer sued Serum Institute of India for ₹5 crore, alleging that the vaccine caused an adverse reaction including neurological impairment. The hospital's institutional ethics committee reportedly concluded that the adverse reaction was not due to the study vaccine.
2020
Indian authorities investigate reported Covishield trial adverse event
The Drugs Controller General of India and the institutional ethics committee at the implementation site were investigating a reported serious adverse event involving a Covishield trial participant. The article does not report a determination about whether the event was caused by the vaccine.
2020
Serum Institute rejects allegation linking trial to volunteer's condition
Serum Institute of India rejected a volunteer's allegation that its COVID-19 vaccine trial caused serious side effects, stating that it found no correlation between the trial and his medical condition. The company also said it would seek damages exceeding Rs 100 crore over the allegations.
2020
Vaccine trial participant sues Serum Institute of India
A participant in the Covishield vaccine trial sued Serum Institute of India, claiming that he suffered serious neurological impairment after receiving the experimental vaccine. He sought Rs 5 crore in compensation; the reported account does not establish that the claimed causal link was determined.
2020
Novavax expands manufacturing agreement with Serum Institute of India
Novavax announced an amendment to its existing agreement with Serum Institute of India under which the institute will also manufacture the antigen component of Novavax’s COVID-19 vaccine candidate NVX-CoV2373. Novavax said planned capacity would bring global manufacturing capacity to more than two billion doses annually by mid-2021.